Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kangai Xiaoshui Ointment is a Traditional Chinese Medicine (TCM) topical preparation developed by the China-Japan Friendship Hospital for the treatment of malignant pleural effusion (MPE). MPE is a common complication in advanced cancer patients, characterized by the accumulation of fluid in the pleural space, which can lead to severe respiratory distress. The ointment is applied externally to the chest wall, where it is intended to facilitate the resorption of pleural fluid and alleviate symptoms such as dyspnea and chest pain. Its formulation typically consists of a combination of herbal ingredients known in TCM for their properties in resolving phlegm, moving qi, and promoting diuresis. Clinical research, including standardization studies at the China-Japan Friendship Hospital, has focused on evaluating its efficacy and safety as a complementary or alternative therapy to conventional drainage and intrapleural treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kangai Xiaoshui Ointment.